Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline

Moretus Research initiated Gilead Sciences with a Strong Buy rating and a $181 price target, citing a disciplined cost base, accelerating pipeline, and strong Q1-25 execution driving margin and EPS outperformance. The report highlights the resilience of Gilead's HIV franchise and the upcoming launch of lenacapavir-PrEP as key drivers for multi-year growth, with consensus estimates underestimating the company's volume and margin expansion potential. Despite insider selling and policy risks, the firm believes Gilead's strong operating leverage and late-stage pipeline create a compelling risk/reward profile.

Analysis

Moretus Research has initiated coverage on Gilead Sciences, Inc. (GILD) with a Strong Buy rating and a $181 price target, signaling a bullish outlook. This positive stance is predicated on several key factors: a disciplined cost structure, an accelerating product pipeline, and expectations of strong Q1-25 execution which are anticipated to drive margin and earnings per share (EPS) outperformance. The resilience of Gilead's existing HIV franchise, coupled with the upcoming launch of lenacapavir-PrEP, is identified as a significant driver for multi-year growth, with Moretus Research believing that current consensus estimates do not fully capture the potential for volume and margin expansion. Furthermore, disciplined Selling, General & Administrative (SG&A) expense reductions and high operating leverage are expected to contribute to sustainable margin accretion and EPS growth exceeding Street expectations, justifying a premium 21x forward price-to-earnings (P/E) multiple. Despite acknowledging risks such as insider selling and potential policy changes, the analysis concludes that Gilead's strong operating leverage and late-stage pipeline catalysts present a compelling risk/reward scenario.

Key Decisions for Investors

• Investors should consider the potential for capital appreciation in Gilead Sciences, given the Strong Buy rating and $181 price target, which suggests significant upside from current levels.
• Key catalysts to monitor include the execution in Q1-25, the launch and market adoption of lenacapavir-PrEP, and further developments in the late-stage pipeline, as these are central to the growth thesis.
• Given the analyst's suggestion to 'buy on volatility,' investors might look for opportunities to initiate or add to positions during periods of market or stock-specific price dips, while keeping the $181 price target in mind.
• While the outlook is positive, investors should remain cognizant of the highlighted risks, specifically insider selling patterns and any emerging policy changes that could impact the pharmaceutical sector or Gilead directly.